Multiple Myeloma Coverage from Every Angle

Recent News

Can PET/CT Imaging Predict Survival in Multiple Myeloma Relapse?
ASCO 2022: Phase II MagnetisMM-3 Trial Focuses on Elranatamab in Resistant Myeloma
ASCO 2022: Update From Cohort A of CARTITUDE-2 on Ciltacabtagene Autoleucel in Myeloma
ASCO 2022: Ixazomib Plus Daratumumab in Elderly Frail Patients With Resistant Multiple Myeloma
ASCO 2022: Early-Phase Study of Talquetamab in Resistant Multiple Myeloma
ASCO 2022: Daratumumab-Based Therapy for High-Risk Smoldering Myeloma
ASCO 2022: Update From CARTITUDE-1 on Ciltacabtagene Autoleucel in Refractory Myeloma
ASCO 2022: Induction Triplet Regimen With or Without ASCT and Maintenance Therapy for Myeloma
Neuroepigenetic Changes and Their Influence on Bortezomib-Induced Peripheral Neuropathy
MARCH Trial: Selinexor Plus Dexamethasone in Chinese Patients With Resistant Myeloma
Neutralizing Antibody Response After COVID-19 Vaccination: Great Variation Among Patients With Myeloma
Cytogenetic Risk Stratification: A Real-World Approach to Optimizing Outcomes in Myeloma
Does Novel Protein Drive Disease Progression in Multiple Myeloma?
Vaccine Plus Co-stimulated T Cells Under Study in Multiple Myeloma
Can MGUS Status Predict the Progression of Multiple Myeloma?
Predicting Progression of Smoldering Multiple Myeloma With Novel Dynamic Model
AACR 2022: Novel IKZF1/3 Degrader Demonstrates Activity in Multiple Myeloma
AACR 2022: Are Bone-Modifying Agents Equitably Administered to Patients With Myeloma?
AACR 2022: Circulating Tumor DNA Mutations and Relapse in Refractory Myeloma
AACR 2022: Selinexor With or Without Duvelisib Under Study in Multiple Myeloma
AACR 2022: Can Novel CAR T Cells Overcome BCMA Antigen Loss in Myeloma?
AACR 2022: Novel Drug Delivery System Under Study in Multiple Myeloma
Survival Update From ICARIA-MM: Isatuximab Plus Pomalidomide and Dexamethasone in Myeloma
Patient-Driven Data Capture Platform May Enhance Multiple Myeloma Research
Can Gene Expression of Myeloma Cells Differ at the Single-Cell Level?
New miRNA-Targeted Therapies Under Study in Multiple Myeloma
Predictive Genetic Marker for Immunomodulatory Treatment of Multiple Myeloma
Belantamab Mafodotin-blmf in Resistant Multiple Myeloma: From the Mayo Clinic
FDA Brief: BCMA-Targeting Immunotherapy Receives Fast Track Designation in Myeloma
Venetoclax Plus Bortezomib and Dexamethasone in Resistant Myeloma: Final Results From BELLINI Trial
Intensified Daratumumab Combination Therapy Before and After ASCT in Myeloma: UK Trial
Ciltacabtagene Autoleucel Approved by the FDA for Treatment of Resistant Multiple Myeloma
Sec61 Translocon: Novel Therapeutic Target in Multiple Myeloma?
Update From Phase III APOLLO Trial of Daratumumab-Based Therapy for Myeloma
Prognostic Value of the MGUS-Like Phenotype in Multiple Myeloma
Dana-Farber Receives $40 Million Grant to Support Multiple Myeloma Research
FDA Brief: Anti-CD47 Antibody Granted Orphan Drug Designation in Myeloma
Addition of Ixazomib to Maintenance Therapy After Autologous Stem Cell Transplantation in Myeloma
Early-Phase Research on Daratumumab-Based Therapies for Resistant Myeloma
Early-Phase Study of Subcutaneous Talquetamab Plus Daratumumab in Resistant Myeloma
Elotuzumab-Based Therapy Plus Transplantation in Newly Diagnosed Myeloma: Phase III Trial Results
Early Research Findings on Novel Bispecific Monoclonal Antibody in Resistant Myeloma
Racial/Ethnic Differences in Patients With Myeloma: Clonal Hematopoiesis, Tumor Markers, and Outcomes
Phase III GMMG-HD7 Trial: Isatuximab-Based Therapy for Newly Diagnosed Myeloma
Activating T Cells With Talquetamab to Treat Multiple Myeloma
Extended Follow-up With Daratumumab-Based Regimen in Newly Diagnosed Myeloma
First-in-Class Targeted Cellular Therapy Under Study in Resistant Multiple Myeloma

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.